Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Department of Hepatopancreatobiliary Surgery, the Third Affiliated Hospital of Soochow University, Changzhou, China.
Cancer Sci. 2021 Jun;112(6):2158-2172. doi: 10.1111/cas.14853. Epub 2021 Apr 8.
Metastasis is a major obstacle to better prognosis in patients with hepatocellular carcinoma (HCC). Mesenchymal-epithelial transition (MET) is the driving force for metastatic colonization in which E-cadherin re-expression is a critical procedure. It has been reported that the loss of paired-related homeobox transcription factor 1 (PRRX1) is required for cancer cell metastasis. However, the role of PRRX1 in MET and how its downregulation triggers E-cadherin re-expression are unknown. In this study, we performed a systematic, mechanistic study regarding the role of PRRX1 in MET of HCC. We observed PRRX1 downregulation in HCC tissues, which correlated with early metastasis and short overall survival. Overexpression of PRRX1 induced epithelial-mesenchymal transition (EMT), but did not promote metastasis formation, while knockdown of PRRX1 promoted metastasis and colonization of circulating HCC cells as shown in animal model. PRRX1 protein levels reversely correlated with E-cadherin levels in HCC cell lines. PRRX1 knockdown promoted E-cadherin re-expression and cell proliferation and inhibited cell invasion and migration. The microarray results showed that PRRX1 deficiency regulated extracellular matrix (ECM) interaction, focal adhesion, TGF-β signaling and cancer pathways. PRRX1 knockdown upregulated paired-like homeodomain 2 (PITX2) and inhibited catenin beta 1 (CTNNB1) and SNAIL family zinc finger 2 (SLUG). Silencing of PITX2 reversed CTNNB1 and SLUG inhibition and E-cadherin re-expression. PITX2 upregulation increased miR-200a and miR-200b/429, which further inhibited the transcription of CTNNB1 and SLUG, respectively, thus abrogating the inhibitory effect on E-cadherin. In conclusion, our data showed that the downregulation of PRRX1 induced E-cadherin re-expression through PITX2/miR-200a/CTNNB1 and PITX2/miR-200b/429/SLUG pathway.
转移是影响肝细胞癌(HCC)患者预后的主要障碍。上皮-间充质转化(MET)是转移定植的驱动力,其中 E-钙黏蛋白的重新表达是一个关键过程。据报道,配对相关同源盒转录因子 1(PRRX1)的丢失是癌细胞转移所必需的。然而,PRRX1 在 MET 中的作用以及其下调如何触发 E-钙黏蛋白的重新表达尚不清楚。在这项研究中,我们对 PRRX1 在 HCC 的 MET 中的作用进行了系统的、机制性的研究。我们观察到 PRRX1 在 HCC 组织中的下调,这与早期转移和总生存期短有关。PRRX1 的过表达诱导上皮-间充质转化(EMT),但不会促进转移形成,而 PRRX1 的敲低则促进了动物模型中循环 HCC 细胞的转移和定植。PRRX1 蛋白水平与 HCC 细胞系中的 E-钙黏蛋白水平呈负相关。PRRX1 敲低促进 E-钙黏蛋白的重新表达、细胞增殖,并抑制细胞侵袭和迁移。微阵列结果表明,PRRX1 缺陷调控细胞外基质(ECM)相互作用、焦点黏附、TGF-β信号和癌症途径。PRRX1 敲低上调同源盒蛋白 2(PITX2),并抑制连环蛋白 β1(CTNNB1)和 SNAIL 家族锌指蛋白 2(SLUG)。PITX2 的沉默逆转了 CTNNB1 和 SLUG 的抑制和 E-钙黏蛋白的重新表达。PITX2 的上调增加了 miR-200a 和 miR-200b/429,分别进一步抑制 CTNNB1 和 SLUG 的转录,从而消除了对 E-钙黏蛋白的抑制作用。总之,我们的数据表明,PRRX1 的下调通过 PITX2/miR-200a/CTNNB1 和 PITX2/miR-200b/429/SLUG 通路诱导 E-钙黏蛋白的重新表达。